BenevolentAl Therapeutics Pipeline and Triage
BAI-5028: Target Product Profile
Product Properties
Mechanism of action
Modality
Primary indication
Patient population
Treatment route/duration
Target Efficacy
Differentiation from other Target
R inhibitors in development
Other factors for differentiation
Profile
CNS penetrate, potent and selective inhibitor with Single Agent & Radiosensitising activity
Small molecule
Glioblastoma Multiforme (GBM)
Newly Diagnosed (MGMT methylated and MGMT unmethylated); Recurrent if Radiotherapy
(RT) approved
Oral, concurrent with RT
For recurrent GBM patients: improvement in PFS at 6 months to >40% (based on RANO
criteria) compared to 25% typical for SOC. For unmethylated GBM patients at first diagnosis:
improvement in overall survival of > 3 months
None in development for GBM or other neurological indications
CNS penetrant
Potential for use in combination with RT and Chemotherapy (CT) in other cancer patients:
cancers where RT is established treatment (examples such as lung, breast, head and neck
cancers).
AI
Benevolent 55View entire presentation